The CIBBIM was created in 1995 as a joint effort of several scientist from different fields of research, surgeons and clinicians , in which the complementation of their respective expertises ensure the achievement of higher goals and top quality standards. In 2007 the CIBBIM opened a new and very successful Nanomedicine Research Program which allowed the center to get involved in several national and international nanomedicine research networks and industrial partnerships. As a consequence, the CIBBIM re-oriented its main research purpose and goals towards the fast-emerging field of nanomedicine and nanotechnology in biomedicine and became the new CIBBIM-Nanomedicine.

The research effort of CIBBIM-Nanomedicine has been focused in two main fields, the nanodiagnosis and the nanotherapy. The final mission of the CIBBIM-Nanomedicine is to foster basic research on biomarker discovery and new therapeutics agents, as well as to provide the Industry and other research groups with the optimal technology for preclinical validation of new nanomedicines.The center is now organized in three interconnected experimental areas covering different aspects of the nanomedicine research and biomedical applications:

• Area 1: Biomarkers and Therapeutics Targets,
• Area 2: Experimental Chemistry and Applied Nanotechnology
• Area 3: Functional Validation and Preclinical Studies.